( NASDAQ-SMALL:ONCS )

News from OncoSec Medical Incorporated A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

Mar 28, 2017, 06:01 ET OncoSec to Present Preclinical Data at the American Association for Cancer Research (AACR) Annual Meeting 2017

OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, will present...


Mar 21, 2017, 14:01 ET OncoSec Medical's Intratumoral Plasmid IL-12 Demonstrates Effectiveness at Enhancing Tumor Immunogenicity in Preclinical Tumor Models

OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, today presented a...


Mar 16, 2017, 16:01 ET OncoSec Announces Second Quarter and YTD Results for Fiscal Year 2017

OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, today announced...


Mar 14, 2017, 06:01 ET OncoSec Announces First Technology Access Program Agreement with Inhibrx

SAN DIEGO, March 14, 2017 /PRNewswire/ -- OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a company developing DNA-based intratumoral...


Mar 07, 2017, 09:22 ET OncoSec to Present at Scientific and Investment Conferences in March

OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, will present...


Mar 02, 2017, 06:01 ET OncoSec to Host Second Quarter Financial Conference Call on March 16, 2017

OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, announced today that...


Feb 27, 2017, 06:01 ET OncoSec Granted FDA Fast Track Designation for ImmunoPulse® IL-12 for the Treatment of Metastatic Melanoma Following Progression on Pembrolizumab or Nivolumab

OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, received Fast Track...


Feb 24, 2017, 06:01 ET OncoSec to Host KOL Event Focused on New ASCO-SITC Melanoma Data and Clinical Strategy on Tuesday, February 28 in New York City

OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, will host a Key...


Feb 23, 2017, 11:30 ET OncoSec Announces Positive Phase II Data Demonstrating Company's ImmunoPulse® IL-12 in Combination with Pembrolizumab Increased Response Rates in Anti-PD-1 Non-Responder Melanoma Patients

OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, today reported new...


Feb 08, 2017, 06:01 ET OncoSec to Present New Clinical Data from Phase 2 Combination Study at ASCO-SITC Clinical Immuno-Oncology Symposium and Corporate Updates at Two Investment Conferences in February

OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, will present new...


Jan 26, 2017, 06:01 ET OncoSec to Present at NobleCon13

OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, today announced that...


Jan 03, 2017, 06:01 ET OncoSec to Present at Investment Conferences in January

OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, announced today that...


Dec 08, 2016, 16:01 ET OncoSec Announces First Quarter Financial Results for Fiscal Year 2017

OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, today announced...


Dec 01, 2016, 06:01 ET OncoSec to Present at the 9th Annual LD Micro Main Event

OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, announced today that...


Nov 17, 2016, 06:01 ET OncoSec Announces Key Corporate Initiatives at Inaugural Investor & Analyst Day on November 17, 2016

OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, will provide updates...


Nov 15, 2016, 06:01 ET OncoSec to Host First Quarter Financial Results Conference Call on December 8, 2016

OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, today announced that...


Nov 11, 2016, 13:01 ET OncoSec Presents Positive Interim Response Data at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2016

OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, today presented new...


Nov 08, 2016, 08:01 ET OncoSec Announces Positive Interim Response Data at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2016

OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, announced today that...


Nov 01, 2016, 06:01 ET OncoSec to Present at Scientific and Investment Conferences and to Host Inaugural Investor and Analyst Day in November

OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, announced today that...


Oct 18, 2016, 06:01 ET OncoSec to Host Investor & Analyst Day on November 17, 2016 Spotlighting Industry-Leading Intratumoral Immunotherapy Pipeline and Next Generation Research and Device Development

OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, announced today that...


Oct 13, 2016, 16:01 ET OncoSec Announces Fourth Quarter and Year End Results for Fiscal Year 2016

OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, today announced...


Oct 13, 2016, 06:01 ET OncoSec Announces Acceptance of Late Breaking Abstract at Upcoming Society for Immunotherapy of Cancer (SITC) Annual Meeting 2016

OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, today announced that...


Oct 10, 2016, 06:00 ET OncoSec to Present at Scientific and Investment Conferences in October

OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, announced today that...


Sep 30, 2016, 06:01 ET OncoSec to Host Fourth Quarter and Fiscal Year End Financial Results Conference Call on October 13, 2016

 OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, today announced...


Sep 06, 2016, 06:00 ET OncoSec Appoints Sharron Gargosky, PhD, to Chief Clinical and Regulatory Officer

 OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, today announced...